Navigation Links
BioMarin to Present at the William Blair Growth Stock Conference
Date:6/8/2011

NOVATO, Calif., June 8, 2011 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Dan Maher, Senior Vice President of Product Development of BioMarin, will present a company update at the William Blair Growth Stock Conference in Chicago on Wednesday, June 15, 2011 at 10:00 a.m. CT.  

Interested parties may access a live audio webcast of the conference call via the investor section of the BioMarin website, www.BMRN.com.  A replay of the call will be archived on the site for one week following the call.

About BioMarinBioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises four approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme® (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme® (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; Kuvan® (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany; and Firdapse™ (amifampridine phosphate), which has been approved by the European Commission for the treatment of Lambert Eaton Myasthenic Syndrome (LEMS). Product candidates include GALNS (N-acetylgalactosamine 6-sulfatase), which is currently in Phase III clinical development for the treatment of MPS IVA, PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in Phase II clinical development for the treatment of PKU, BMN-701, a novel fusion protein of insulin-like growth factor 2 and acid alpha glucosidase (IGF2-GAA), which is currently in Phase I/I
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. BioMarin to Present at the Jefferies Global Healthcare Conference
2. BioMarin to Present at the Bank of America Merrill Lynch Healthcare Conference
3. BioMarin Announces First Quarter 2011 Financial Results
4. BioMarin to Present at the Deutsche Bank Healthcare Conference
5. BioMarin to Present at the Barclays Global Healthcare Conference
6. BioMarin to Present at the Cowen Health Care Conference
7. BioMarin to Present at the Citi Global Healthcare Conference
8. BioMarin Announces Fourth Quarter and Full Year 2010 Financial Results
9. BioMarin Initiates Pivotal Phase 3 Trial for GALNS for the Treatment of MPS IVA
10. BioMarin to Host Fourth Quarter and Full Year 2010 Financial Results
11. BioMarin Initiates Phase 1/2 Trial for BMN 701 for the Treatment of Pompe Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... TORONTO , May 22 2015 /CNW/ - The Taskforce ... are very appreciative of all the hard work that the ... the past six months. This program recognizes the needs of ... receive at least $75,000 a year, tax free, with annual ... will be eligible for annual payments of $100,000 based on ...
(Date:5/22/2015)... mayo de 2015 Dipexium Pharmaceuticals, ... farmacéutica de fase tardía centrada en el ... 0.8%), y colaboradores de investigación clínica, han ... el diseño innovador de los ensayos pivotales ... evalúan Locilex®, su nuevo péptido de antibiótico ...
(Date:5/22/2015)... 2015  Effective staffing of key marketing services ... success. Research and consulting leader ... pharmaceutical and biotech marketing managers with metrics detailing ... are being channeled into marketing operations of global ... utilize this report to benchmark their own resource ...
Breaking Medicine Technology:Dipexium anuncia presentación en el séptimo Simposio Internacional sobre el Pie Diabético 2Dipexium anuncia presentación en el séptimo Simposio Internacional sobre el Pie Diabético 3Dipexium anuncia presentación en el séptimo Simposio Internacional sobre el Pie Diabético 4Dipexium anuncia presentación en el séptimo Simposio Internacional sobre el Pie Diabético 5Dipexium anuncia presentación en el séptimo Simposio Internacional sobre el Pie Diabético 6Effective Marketing Services Group Critical for Pharmaceutical Brand Recognition 2
... Md., Sept. 26, 2011 Science, public ... Administration. Information in this document is designed for credentialed journalists. ... September 26, 2011. (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO ... contain any regulatory or enforcement actions due to legal limitations. ...
... (NYSE: LLY ) announced today that a new ... study showed that continuation maintenance therapy with ALIMTA ® ... in patients aged 70 years or older with advanced nonsquamous ... lung cancer. Results from the new analysis ...
Cached Medicine Technology:FDA News & Notes - Week of September 26, 2011 2ALIMTA Helped Keep Most Common Form of Lung Cancer at Bay In Elderly Patients 2ALIMTA Helped Keep Most Common Form of Lung Cancer at Bay In Elderly Patients 3ALIMTA Helped Keep Most Common Form of Lung Cancer at Bay In Elderly Patients 4ALIMTA Helped Keep Most Common Form of Lung Cancer at Bay In Elderly Patients 5ALIMTA Helped Keep Most Common Form of Lung Cancer at Bay In Elderly Patients 6ALIMTA Helped Keep Most Common Form of Lung Cancer at Bay In Elderly Patients 7
(Date:5/22/2015)... Mountain Point Medical Center, a campus of ... on Friday, May 29, 2015 at 11 a.m., followed by ... new medical center, set to officially open on June 1, ... 84043. , “The opening of Mountain Point Medical Center ... County community,” said Kent Loosle, CEO of Mountain Point Medical ...
(Date:5/22/2015)... Omar Ahmad Barrada, a junior at Milton ... 2015 Congress of Future Medical Leaders in Boston, Mass. ... “America’s highest achieving high school students.” , “I’m excited ... goals and learn better study habits,” said Omar. “The ... we can ask the surgeons questions.” , The goal ...
(Date:5/22/2015)... 2015 Family, friends, students, colleagues, mentors ... oncologist, Dr. LaSalle D. Leffall, on Monday, May 18, ... after Grand Rounds in the hospital’s Tower Auditorium. Leffall’s ... the auditorium, trying to keep the secret. “I’d like ... sees me, he’ll know something is up,” she said. ...
(Date:5/22/2015)... WA (PRWEB) May 22, 2015 According to ... of all generations are equally as likely to worry about ... Millennials, 75% Gen X, 77% Boomers, 69% Silent Generation), which ... agree they are scared of aging, particularly Millennials (47%), Gen ... by Harris Poll in April, 2015 among more than 2,000 ...
(Date:5/22/2015)... According to Berks and Beyond , Pennsylvania ... totaling almost 2,500 confirmed drug deaths, as reported on May ... 2,489 deaths stemming from legal and illegal drug use in ... every day to fatal overdoses or other drug related deaths. ... of the most rife with drug related deaths. The city, ...
Breaking Medicine News(10 mins):Health News:Mountain Point Medical Center, a Campus of Jordan Valley Medical Center, Hosts Ribbon Cutting Ceremony and Community Celebration on Friday, May 29, 2015 2Health News:Milton Hershey School Student Chosen for Congress of Future Medical Leaders 2Health News:Colleagues Surprise Dr. LaSalle Leffall with 85th Birthday Celebration 2Health News:New Study Reveals America’s Fear of Aging 2Health News:New Study Reveals America’s Fear of Aging 3Health News:Philadelphia Ranks Among the Tops Cities in Penn. for Drug Deaths 2
... service helps Medicare beneficiaries avoid loss of ... to pay for prescription medications, ARLINGTON, Va., Oct. ... services, and Human Arc (Cleveland, OH),a leading expert in ... Medicare Part D plan sponsors,retained their services to redeem ...
... SAN FRANCISCO While some targeted therapies ... chemical pathways occurring within cancer cells work well ... better when teamed with other targeted and conventional therapies. ... on Molecular Targets and Cancer Therapeutics, multiple-target applications of ...
... source of major discoveries and breakthroughs in biology, not ... processes. Delegates at a recent research conference organised by ... how technology capable of analysing animal genes across the ... human society. , In breeding both domestic and ...
... WASHINGTON, Oct. 24 ICx Technologies, a developer ... announced,today that it has entered into a new ... Diagnostics to develop diagnostic,sensors. The goal is to ... developed by ICx, and know-how for use in,Siemens, ...
... 24 CME LLC (http://www.CMELLC.com ), a,leading ... 1978, today announced it has been granted five-year ... an approved sponsor of,continuing medical education for APA ... approval as part of the APA,s,Continuing Education in ...
... have discovered a way to use a simple blood ... which gives little warning and is almost always fatal ... Public Library of Science (PLoS), represents the collaborative work ... Diagnostics. , TAAs occur in the part of the ...
Cached Medicine News:Health News:Vangent and Human Arc Win Business With 13 Medicare Part D Plans 2Health News:Vangent and Human Arc Win Business With 13 Medicare Part D Plans 3Health News:Vangent and Human Arc Win Business With 13 Medicare Part D Plans 4Health News:Combination targets: some drugs may work best when they work together 2Health News:Combination targets: some drugs may work best when they work together 3Health News:Combination targets: some drugs may work best when they work together 4Health News:Combination targets: some drugs may work best when they work together 5Health News:Combination targets: some drugs may work best when they work together 6Health News:Combination targets: some drugs may work best when they work together 7Health News:Not just humans benefit from animal biotechnology 2Health News:Not just humans benefit from animal biotechnology 3Health News:ICx Technologies and Siemens Medical Solutions Diagnostics Enter In Vitro Diagnostics Development and License Option Agreement 2Health News:CME LLC Granted Five-Year Full Approval by the American Psychological Association 2Health News:A new key to detecting deadly aortic aneurysms 2
Series I Small Joint Arthroscopy Hand Instruments feature small yet durable instruments specifically designed for small joint arthroscopy. They are available in a variety of low profile styles: strai...
Series I Small Joint Arthroscopy Hand Instruments feature small yet durable instruments specifically designed for small joint arthroscopy. They are available in a variety of low profile styles: strai...
Series I Small Joint Arthroscopy Hand Instruments feature small yet durable instruments specifically designed for small joint arthroscopy. They are available in a variety of low profile styles: strai...
Series I Small Joint Arthroscopy Hand Instruments feature small yet durable instruments specifically designed for small joint arthroscopy. They are available in a variety of low profile styles: strai...
Medicine Products: